If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
88.00    1.90 (2.21%)
Bid:
88.90
Ask:
90.00
Spread: 1.10 (1.237%)
Market Cap: £144.27m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

11 Feb 2008 07:01

Yule Catto & Co PLC11 February 2008 Yule Catto & Co. plc Sale of James Robinson Yule Catto is an international producer of speciality chemicals, supplied toglobal customers for use in a wide range of industries includingpharmaceuticals, FMCG, paints and adhesives Yule Catto & Co plc ("Yule Catto" or the "Company") is pleased to announce thatit has exchanged conditional contracts with Vivimed Labs Limited ("Vivimed") forthe sale of the entire issued share capital of James Robinson Limited and otherassociated assets (together "James Robinson") for a consideration of $21.15million plus working capital of approximately $4.5 million. The considerationwill be paid as to $17.15 million plus the working capital amount in cash atcompletion and a further $4 million into escrow pending successful completion ofcertain product transfer arrangements. The completion of the sale is conditional on, amongst other things, Vivimedobtaining shareholder approval for the acquisition which is expected to beobtained by mid April 2008. The proceeds of the sale received by Yule Catto will be used to reduce theCompany's borrowings, and the transaction will be earnings accretive James Robinson carries on the development, manufacture and supply ofphotographic and photochromic chemicals and hair and other dyes. In the twelvemonths to 31 December 2006 it had sales of £17.8 million, an operating profit of£0.82 million and gross assets of £3.0 million. The James Robinson management team led by Dr Richard Smith will continue to runthe business. In addition, Yule Catto anticipates disposing of its interest in James RobinsonIndia (Private) Limited to its joint venture partner following the completion ofthe sale of James Robinson for a consideration of some $1.5 million. Adrian Whitfield, Chief Executive commented: "This sale is in line with YuleCatto's corporate strategy of delivering improved shareholder value from itsImpact Chemicals activities". 11 February 2008 ENQUIRIES: YULE CATTO Tel: 01279 442791Adrian Whitfield, Chief ExecutiveDavid Blackwood, Finance Director COLLEGE HILL Tel: 020 7457 2020Gareth DavidAnthony Parker This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Nov 20201:34 pmRNSDirector/PDMR Shareholding
16th Oct 202010:33 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSQ3 Trading Update
7th Oct 20209:20 amRNSHolding(s) in Company
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.